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Abstract
In addition to changes in motor and sensory function, individuals with spinal cord injury (SCI) experience
immunological changes. These changes are clinically significant, as infections are the leading cause of
death for this population. Along with increased infections, inflammation is commonly observed in persons
with SCI, where it may promote many common medical consequences. These include elevated risk of
cardiovascular disease, impaired wound healing, diabetes and neuropathic pain. It has also been proposed
that chronic inflammation dampens neurological recovery. In order to identify therapeutic strategies to
improve immune function, we need a greater understanding of the molecular changes that occur in immune
cells after SCI. The purpose of this mini-review is to discuss two recent studies that used functional
genomics to investigate gene expression in circulating leukocytes isolated from persons with SCI. In the
future, the molecular pathways that are altered after SCI may be targeted to improve immunological
function, as well as overall health and functional recovery, after SCI.
Keywords: traumatic spinal cord injury, inflammation, immune cells, functional genomics, gene
expression, autoimmunity, microarray, chronic spinal cord injury
Traumatic Spinal Cord Injury (SCI)
There are an estimated 760,000–2.5 million persons living with traumatic SCI globally and more than
350,000 persons in the United States (National Spinal Cord Injury Statistical Center, 2017; Kumar et al.,
2018). In the US, the average age at injury is 43 years old. The most common mechanisms of injury are
motor vehicle accident (38%), followed by falls (32%), violence (14%), sports (8%) and other (8%)
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(National Spinal Cord Injury Statistical Center, 2017). The most common levels of injury are cervical
(54%), thoracic (35%), and lumbar (10%). Unfortunately, there is no Food and Drug Administration
(FDA) approved pharmacological therapy for SCI and living with SCI therefore imposes significant
physical, psychosocial and economic burdens for patients and their families.
The gold standard clinical exam to classify motor and sensory function after SCI is the International
Standards for Neurological Classification of SCI (ISNCSCI) exam (Kirshblum and Waring, 2014; Ahuja et
al., 2017). The ISNCSCI exam tests motor and sensory function throughout the body and based on exam
findings, spinal cord injuries are classified with the American Spinal Injury Association (ASIA)
Impairment Scale (AIS) grades A–E (Table 1): A indicates a clinically complete injury with no motor or
sensory function preserved in sacral segments S4–5, B–D indicate incomplete injuries, with some motor or
sensory function preserved below the neurological level of injury, and E indicates a normal exam (Table 1)
(Kirshblum and Waring, 2014). Different tools are used to reflect abilities to perform activities of daily
living after SCI. One widely used tool is the Spinal Cord Independence Measure, which is a standardized,
validated rating scale that measures the functional status or improvement in performing daily activities for
people with SCI and has domains related to self-care, respiration, bowel and bladder care, and mobility
(Catz et al., 1997; Itzkovich et al., 2007). Another more recently developed tool that was designed to be
used as a patient reported outcome is the SCI-Functional Index (SCI-FI), which describes aspects and
modes of mobility, self-care, and fine motor function (Jette et al., 2012; Fyffe et al., 2016).
Despite advances in clinical care, the National SCI Statistical Center (NSCISC) estimates that life
expectancy for persons with SCI remains lower than for able-bodied persons and depends on age at injury,
injury severity, injury level, ventilator use, general comorbidities and other factors (National Spinal Cord
Injury Statistical Center, 2017). Life expectancy after SCI also changes with time from initial injury
(National Spinal Cord Injury Statistical Center, 2017). For example, data from the NSCISC estimates that
life expectancy for a person with a cervical level injury sustained at age 25 who survived the initial 24
hours after their injury (without ventilator use) was 31–36 years, while life expectancy for an able-bodied
person at age 25 was 54.8 years (Ahuja et al., 2017; National Spinal Cord Injury Statistical Center, 2017).
Data from the NSCISC estimates that life expectancy for a person with a cervical level injury sustained at
age 70 who survived the initial 24 hours after their injury (without ventilator use) was 6.5–8 years, while
life expectancy for an able-bodied person at age 70 was 15.6 years (National Spinal Cord Injury Statistical
Center, 2017).
Traumatic SCI Compromises More Than Motor and Sensory Function
Infections (genitourinary or respiratory) are the leading cause of death for persons with SCI and are also
the most common cause of re-hospitalization after SCI (DeVivo et al., 1993; Cardenas et al., 2004; DeJong
et al., 2013; National Spinal Cord Injury Statistical Center, 2017). Recent data has also identified
infections as an independent risk factor for poor neurological recovery (Failli et al., 2012). Along with
increased infection rates, inflammation is commonly observed in the SCI population and may play a role in
the pathogenesis of many common medical consequences of SCI, including accelerated atherogenesis and
osteoporosis, impaired wound healing, type II diabetes, and neuropathic pain (Bauman and Spungen,
2000). In humans, elevated numbers of inflammatory cells in the spinal cord were identified years after
initial injury (Fleming et al., 2006). Persistent elevated levels of intraspinal and systemic inflammatory
mediators may also oppose neurological recovery (Schwab et al., 2014). Impaired immune cell function ex
vivo has also been reported from persons living with SCI (Nash, 1994; Campagnolo et al., 2000).
Autoreactive antibodies have also been described in persons with SCI (Schwab et al., 2014).
Impaired Neuroimmune Interactions after SCI May Contribute to Increased
Rates of Infection and Chronic Inflammation
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The autonomic nervous system (ANS) innervates most visceral organs (heart, lung, liver, and intestine)
and also regulates immune system function (spleen, lymph nodes, bone marrow) (Figure 1). In able-
bodied people, the ANS regulates homeostasis through synergistic and coordinated activation of the
sympathetic nervous system (SNS) and parasympathetic nervous system (PNS) (Pavlov and Tracey, 2017).
In persons with SCI, impaired ANS regulation of organ systems below the injury level are associated with
serious medical consequences, ranging from autonomic dysreflexia to adverse changes in metabolism
(Bauman and Spungen, 2000). A growing body of evidence shows that the ANS also regulates immune
system function. Both the PNS and SNS innervate immune organs, such as the spleen and lymph nodes,
and there are many points of regulated interaction between the nervous and immune systems throughout
the body (Pavlov and Tracey, 2017). Based on these physiological interactions, a causal relationship has
been proposed between SCI level-dependent changes in the ANS and changes in immune system function
that include chronic inflammation, changes in adaptive immunity and immunosuppression (Schwab et al.,
2014). SNS fibers exit the spinal cord and innervate organs of the immune system at T5, and persons with
spinal cord injuries rostral to T5 have the most immunological symptoms (Campagnolo et al., 2000; Failli
et al., 2012; Schwab et al., 2014).
What are the Molecular Causes of Immunological Symptoms after SCI?
Despite the medical importance of immune function after SCI, to date there have been only two original
research studies that systematically investigated gene expression in immune cells isolated from persons
with chronic SCI (Saltzman et al., 2013; Herman et al., 2018). The first study by Saltzman and colleagues
compared whole blood gene expression in men with chronic motor complete (AIS A) SCI (at least one
year from initial injury) to able-bodied (AB) men (N = 13, 7 respectively) (Saltzman et al., 2013). RNA
was extracted from whole blood and gene expression levels were quantified by microarray using the HG-
U133A Plus 2.0 GeneChip (Affymetrix). The study identified 1453 genes that were differentially
expressed in men with SCI. Using Ingenuity Pathway Analysis to provide a functional description of
differentially expressed genes, Saltzman and colleagues focused their discussion on a gene network related
to lymphoid tissue structure, which is regulated by the master transcription factor nuclear factor kappa B
(NF-κB). They showed enhanced expression of the autoimmunity-promoting cytokines B-cell maturation
antigen (BCMA), B cell activating factor of the tumor necrosis factor (TNF) family (BAFF) and a
proliferation-inducing ligand (APRIL) in this network by microarray and qPCR, consistent with sparse but
continued literature demonstrating serological signs of autoimmunity after SCI, such as anti-central
nervous system (CNS) antibodies (Saltzman et al., 2013; Schwab et al., 2014). Other key genes of the
pathway included several members of the TNF receptor superfamily.
In order to provide a deeper understanding of the molecular mechanisms underlying immunological
symptoms after SCI, we set out to perform a larger (by participant number) and deeper (by analytical
scope) study of gene expression in leukocytes of persons with chronic SCI (Herman et al., 2018). We
recruited adults with chronic SCI, (at least one year from initial injury) (Figure 1). In this study, 58% of
participants had cervical, 36% had thoracic and 6% had lumbar spinal cord level injuries (N = 25 male, 6
female). For comparison, we recruited 26 able-bodied persons (N = 19 male, 7 female). Participants in this
study mostly had AIS A injuries, followed by D, C and B respectively. Since we were studying immune
function, persons with clinically significant infections were excluded from participating in the study. We
collected data from participants about their medical histories and current medication regimens. Participants
were asked to contribute blood samples at two study visits held 6 months apart. Most participants (N =
24/31) completed both study visits, and able-bodied adult participants without SCI (N = 26) were used as
the comparison group.
RNA was extracted from whole blood and gene expression levels were quantified by microarray using the
using the HT-12v4 Expression BeadChip (Herman et al., 2018). We first determined that within the SCI
group, gene expression did not differ significantly between the study visits that occurred 6 months apart.
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We then compared the transcriptional profiles of individuals living with chronic SCI to able-bodied
individuals. Hierarchical clustering of differentially expressed genes showed global differences in
leukocytes from persons with SCI as compared to able-bodied participants. We discovered 1815 genes that
were differentially expressed between the groups (false discovery rate (FDR) = 0.05) (Figure 1).
Participants with SCI levels rostral to T5, where SNS disruption would occur, had more differentially
expressed genes (N = 2226) compared to able-bodied participants. For the complete list of differentially
expressed genes, see Supplementary Table 1 in Herman et al. (2018).
Characterization of Differentially Expressed Genes in Persons with High Spinal
Cord Level Injuries
Immunologists have recently developed a series of empirical modules comprised of genes co-expressed in
blood cells across different disease states (Chaussabel et al., 2008). Modules were created by experimental
observation of gene expression in blood of patients with many different inflammatory or autoimmune
diseases genes, so that genes that were expressed in a consistently coordinated manner across diseases, for
example, up- or down-regulated together, are clustered together into a module (Chaussabel et al., 2008).
This modular analysis assumes that genes that change coordinately in expression across different diseases
likely have related or coordinated biological functions and also presents an opportunity to compare
changes in the gene modules across disease states (Chaussabel et al., 2008). Modules are named according
to the known function of genes within it and unnamed modules contain genes whose function is not yet
determined. We assigned the genes differentially expressed in persons with SCI levels rostral to T5 to the
previously established modules (Chaussabel et al., 2008). We found an under-expression of modules
related to many immune cell types including Natural Killer (NK) cells, B cells and T cells. Conversely, we
identified elevation of a monocyte module, as well as elevation of six different inflammation modules. For
a list of all differentially expressed genes by module, see Supplementary Table 1 in Herman et al. (2018).
NK cells are innate immune system lymphocytes responsible for killing virally infected cells or tumor
cells, and they also have modulating effects on other immune cell types. Dramatic downregulation of NK
cell genes and elevation of pro-inflammatory genes in persons with SCI levels rostral to T5 were reflected
by many independent bioinformatics approaches. For example, killer inhibitory receptors (KIRs) are most
commonly found on NK cells and are also found on other immune cell subsets. KIRs can activate or
inhibit NK cells from killing their target cells. In this study, we found that 5 of the 36 most significantly
downregulated genes in persons with SCI levels rostral to T5 were KIR3DL1, KIR3DL3, KIR2DL4,
KIR2DL1 and KIR2DS5. For a complete list of significantly up- and down-regulated genes, see
Supplementary Table 1 in Herman et al. (2018). We used the bioinformatics resource “Enrichr”, which
allows a gene list to be analyzed simultaneously by multiple bioinformatics tools to reveal the functions of
differentially expressed genes (Chen et al., 2013). The Kyoto Encyclopedia of Genes and Genomes
(KEGG) bioinformatics platform also showed that the “NK cell mediated cytotoxicity” pathway was
significantly enriched in genes differentially expressed in participants with SCI at levels rostral to T5. For
a list of pathways significantly enriched in differentially genes, see Supplementary Table 1 in Herman et
al. (2018).
Conversely, several pro-inflammatory genes were among the top 50 upregulated differentially expressed
genes in study participants with SCI rostral to T5, including JAK2, a protein tyrosine Janus kinase family
member. JAK2, as well as other elevated genes, such as the beta-adrenergic receptor, are targets of FDA-
approved drugs. Toll like receptors (TLR) are innate pattern recognition receptors critical for maintaining
immunity against pathogens and TLR activation promotes production of inflammatory mediators (Foster
and Medzhitov, 2009). TLR modulating agents are also in clinical trials for indications such as
autoimmune disease and inflammation (Gao et al., 2017). We also discovered that TLR signaling pathways
were highly enriched among genes upregulated in participants with SCI rostral to T5. Interestingly, there
are TLR modulating agents in clinical trial for sepsis, which is associated with infections and is a major
cause of mortality for persons with SCI (Gao et al., 2017; National Spinal Cord Injury Statistical Center,
7/11/2019 Altered leukocyte gene expression after traumatic spinal cord injury: clinical implications
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC6126132/?report=printable 5/13
2017). Adrenomedullin, a vasodilator that is increased in sepsis, was also upregulated in participants with
SCI rostral to T5 (see Supplementary Table 1 in Herman et al. (2018)). A recent phase I clinical trial of
anti-adrenomedullin antibodies was performed, with the hopes of developing them as a therapeutic agent
in sepsis (Geven et al., 2018a, b). Many immune cells, including NK cells, are highly responsive to
adrenaline and another gene of particular interest that was upregulated in participants with SCI rostral to
T5 is the beta-2 adrenergic receptor. A recent study demonstrated that elevated noradrenergic signaling
leads to immunosuppression in an animal model of acute SCI (Pruss et al., 2017).
We identified transcription factors that are known to regulate genes differentially expressed in individuals
with SCI at levels ≥ T5 using the TRANSFAC database (Matys et al., 2006; Chen et al., 2013). The top 10
transcription factor identified by TRANSFAC were: E2F1, FOXC1, PPARg, PITX2, NRF1, STAT3,
GATA2, LEF1, GATA3, and GFl1. Many of these transcription factors are elevated in individuals with
metabolic syndrome. For example, E2F1 and STAT3 binding motifs were also upregulated in circulating
blood cells isolated from insulin resistant Latino adults with metabolic syndrome (Tangen et al., 2013).
This was consistent with data generated independently by the PANTHER bioinformatics platform, which
identified the insulin pathway as enriched among upregulated differentially expressed genes in individuals
with SCI at levels T5 and above (see Figure 4 in Herman et al. (2018)). Members of the peroxisome
proliferator-activated receptors (PPAR) family of nuclear hormone receptors are transcription factors
widely considered in the treatment of type II diabetes and in particular, PPAR gamma is expressed mostly
in adipose (Bugge and Holst, 2017). PPARs also play a role in secondary inflammation after SCI and
clinically used anti-inflammatory agonists of PPAR had beneficial effects in rodent models of SCI
(McTigue et al., 2007; Genovese et al., 2009; Zhang et al., 2010, 2011; Li et al., 2013, 2016, 2017; Bugge
and Holst, 2017). An inhaled version of DNAzyme that targets GATA3, which is critical for T helper type
2 (TH2) T cell development, was used in a phase I study of asthma (Homburg et al., 2015; Krug et al.,
2015). Elevated expression of LEF1, which is a key regulator of the WNT pathway, was identified to
associate with worse outcomes in B cell acute lymphoblastic leukemia (ALL) patients, while LEF1
inactivation was associated with T cell ALL (Gutierrez et al., 2010; Kuhnl et al., 2011).
We also confirmed several genes first identified by Saltzman and colleagues as differentially expressed in
whole blood of persons with SCI in participants with SCI rostral to T5 (Saltzman et al., 2013). These
included CD36, which is a platelet thrombospondin receptor, the autoimmune promoting receptor B cell
maturation antigen (BCMA/TNFRSF17), inositol-trihophate-3-kinase B (ITPKB) that regulates inositol
metabolism, MAP Kinase Activating Death Domain (MADD) that interacts with the TNF-alpha receptor 1
and interacting partners of the NF-κB pathway. Saltzman and colleagues also implicated the PPAR gamma
pathway, as we discussed above. We did not find evidence of elevated the cytokines APRIL (TNFSF13) or
BAFF (TNFSF13B). These differences are likely due to relatively small participant group sizes with
different clinical and demographic characteristics.
Novel Mechanistic Insights into the Causes Underlying Symptoms of Immune
Dysfunction in Persons Living with SCI
Here we discovered broad changes in innate and adaptive immune cell genes. Modular and pathway
analyses identified downregulation of NK cells genes, which we were particularly interested in, because
NK cells are critical for fighting pathogens, previous studies showed NK cell defects ex vivo from persons
with tetraplegia, and infections are the leading cause of mortality for persons with SCI (DeVivo et al.,
1993; Nash, 1994; Campagnolo et al., 2000). Modular analysis also identified upregulation of
inflammatory genes. Multiple pathway analyses identified elevated TLR pathway genes, which promote
inflammation. Other elevated inflammatory genes we discovered in persons with SCI included targets of
FDA-approved drugs, including JAK2 and the beta-adrenergic receptor, which has been implicated in
neuroimmune signaling in able-bodied and SCI populations (Schwab et al., 2014; Pavlov and Tracey,
2017). Transcription factors regulating genes differentially expressed in persons with SCI rostral to T5
included PPARg, which is a clinical target in diabetes and has been implicated in inflammation in animal
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models of SCI. Finally, there were some common observations between the 2 studies discussed, including
upregulation of the autoimmunity promoting cytokine BCMA and in a broader sense, the upregulation of
pro-inflammatory signaling pathways.
Going forward, we intend to identify the specific immune cell subsets in which inflammatory genes are
elevated. We will also perform mechanistic studies to evaluate functional changes in NK cells (and other
leukocyte subsets) from persons with SCI to determine which of the differentially expressed gene
pathways is critical for maintaining health, like eliminating viral infections or promoting inflammation.
These data may also be relevant to the increasing number of clinical studies or trials that aim to promote
functional recovery for persons living with chronic SCI, where inflammation may play an antagonistic
role. Taken together, these data suggest potential mechanisms for therapeutic strategies to improve immune
function, promote survival, health and perhaps even functional recovery in persons living with SCI.
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Table 1
American Spinal Injury Association Impairment Scale (AIS)
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Figure 1
Open in a separate window
Neuroimmune interactions relevant to spinal cord injury (SCI).
(A) Sensory dermatomes that are innervated at each spinal level are indicated by color, which matches the color scheme in
B. (B) Schematic representation of the brain and spinal cord that demonstrates spinal levels contributing autonomic
nervous system (ANS) innervation to visceral organs and immune system tissues. Dark blue lines show nerve fibers
carrying parasympathetic nervous system (PNS) innervation via the vagus nerve. Other lines show nerve fibers carrying
sympathetic nervous system (SNS) innervation to target organs following synapses at the sympathetic trunk, shown in
black immediately to the right of the spinal column. Color Key: Green: Cervical, pink: thoracic, orange: lumbar, blue:
sacral. (C) Able-bodied (AB) individuals or individuals with chronic SCI were recruited for this study and blood collected
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for whole blood gene expression. (D) There were 1815 and 2226 differentially expressed genes between the AB and SCI
groups and the AB and T5 and above SCI group (upper). A cartoon of a heat map is shown for differentially expressed
genes that were then analyzed at the individual, pathway and modular levels (lower).
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